| Year |
Citation |
Score |
| 2022 |
Thangavelu G, Zaiken MC, Mohamed FA, Flynn R, Du J, Rhee SY, Riddle MJ, Aguilar EG, Panoskaltsis-Mortari A, Sanders ME, Blazar BR. Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease. Frontiers in Immunology. 13: 765319. PMID 35359939 DOI: 10.3389/fimmu.2022.765319 |
0.589 |
|
| 2022 |
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, et al. BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. PMID 35226736 DOI: 10.1182/blood.2021014557 |
0.566 |
|
| 2021 |
Levy RB, Mousa HM, Lightbourn CO, Shiuey EJ, Latoni D, Duffort S, Flynn R, Du J, Barreras H, Zaiken M, Paz K, Blazar BR, Perez VL. Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease. International Journal of Molecular Sciences. 23. PMID 35008621 DOI: 10.3390/ijms23010184 |
0.486 |
|
| 2019 |
Thangavelu G, Du J, Paz KG, Loschi M, Zaiken MC, Flynn R, Taylor PA, Kirchmeier AK, Panoskaltsis-Mortari A, Luznik L, MacDonald KP, Hill GR, Maillard I, Munn DH, Serody JS, et al. Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease. Blood. PMID 31697815 DOI: 10.1182/Blood.2019000032 |
0.683 |
|
| 2019 |
Sinha RK, Flynn R, Zaiken M, Paz K, Gavin AL, Nemazee D, Fernández JA, Xu X, Griffin JH, Blazar BR. Activated Protein C Ameliorates Chronic Graft-Versus-Host Disease by PAR1-dependent Biased Cell Signaling on T-cells. Blood. PMID 31243040 DOI: 10.1182/Blood.2019001259 |
0.626 |
|
| 2019 |
Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, et al. Targeting PI3Kδ Function For Amelioration of Murine Chronic Graft-Versus-Host Disease. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 30748099 DOI: 10.1111/Ajt.15305 |
0.721 |
|
| 2018 |
Verghese DA, Chun N, Paz K, Fribourg M, Woodruff TM, Flynn R, Hu Y, Xiong H, Zhang W, Yi Z, Du J, Blazar BR, Heeger PS. C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. Jci Insight. 3. PMID 30568034 DOI: 10.1172/Jci.Insight.124646 |
0.746 |
|
| 2018 |
Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Culter CS, Koreth J, et al. Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease. Blood. PMID 30279226 DOI: 10.1182/Blood-2018-03-839993 |
0.654 |
|
| 2018 |
Radojcic V, Paz K, Chung J, Du J, Perkey ET, Flynn R, Ivcevic S, Zaiken M, Friedman A, Yan M, Pletneva MA, Sarantopoulos S, Siebel CW, Blazar BR, Maillard I. Notch signaling mediated by Delta-like1/4 ligands controls the pathogenesis of chronic graft-versus-host disease in mice. Blood. PMID 30181175 DOI: 10.1182/Blood-2018-03-841155 |
0.665 |
|
| 2018 |
Wu Y, Schutt S, Paz K, Zhang M, Flynn RP, Bastian D, Sofi MH, Nguyen H, Dai M, Liu C, Chang YJ, Blazar BR, Yu XZ. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. Blood. PMID 29530952 DOI: 10.1182/Blood-2017-06-789321 |
0.572 |
|
| 2018 |
Du J, Flynn R, Paz K, Ren HG, Ogata Y, Zhang Q, Gafken PR, Storer BE, Roy NH, Burkhardt JK, Mathews W, Tolar J, Lee SJ, Blazar BR, Paczesny S. Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood. PMID 29348127 DOI: 10.1182/Blood-2017-08-800623 |
0.631 |
|
| 2017 |
Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, et al. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. Jci Insight. 2. PMID 28614794 DOI: 10.1172/Jci.Insight.92111 |
0.706 |
|
| 2017 |
Du J, Paz K, Thangavelu G, Schneidawind D, Baker J, Flynn R, Duramad O, Feser C, Panoskaltsis-Mortari A, Negrin RS, Blazar BR. Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood. PMID 28416503 DOI: 10.1182/Blood-2016-11-752444 |
0.709 |
|
| 2017 |
Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, Alexander KA, Meng J, Roy S, Panoskaltsis-Mortari A, Loschi M, Hill GR, Serody JS, Maillard I, Miklos D, et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. Blood. PMID 28254742 DOI: 10.1182/Blood-2017-01-758854 |
0.635 |
|
| 2017 |
Lin A, Mathews C, Haller M, Brusko T, Atkinson M, Flynn R. 2431 Journal of Clinical and Translational Science. 1: 37-37. DOI: 10.1017/cts.2017.136 |
0.354 |
|
| 2016 |
Weiss JM, Chen W, Nyuydzefe MS, Trzeciak A, Flynn R, Tonra JR, Marusic S, Blazar BR, Waksal SD, Zanin-Zhorov A. ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. Science Signaling. 9: ra73. PMID 27436361 DOI: 10.1126/Scisignal.Aad8953 |
0.68 |
|
| 2016 |
McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KP, Hill GR, Luznik L, Serody JS, Murphy WJ, Maillard I, Munn DH, Turka LA, Koreth J, Cutler CS, Soiffer RJ, et al. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5 dependent manner. Blood. PMID 27385791 DOI: 10.1182/Blood-2016-05-715896 |
0.678 |
|
| 2016 |
Zanin-Zhorov A, Flynn R, Waksal SD, Blazar BR. Isoform-specific targeting of ROCK proteins in immune cells. Small Gtpases. 0. PMID 27254302 DOI: 10.1080/21541248.2016.1181698 |
0.553 |
|
| 2016 |
Li W, Liu L, Gomez A, Zhang J, Ramadan A, Zhang Q, Choi SW, Zhang P, Greenson JK, Liu C, Jiang D, Virts E, Kelich SL, Chu HW, Flynn R, et al. Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. Jci Insight. 1. PMID 27195312 DOI: 10.1172/Jci.Insight.86660 |
0.634 |
|
| 2016 |
Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, et al. Targeted Rho-associated kinase 2 (ROCK2) inhibition decreases clinical and immune pathology of murine and human chronic GVHD through Stat3-dependent mechanism. Blood. PMID 26983850 DOI: 10.1182/Blood-2015-10-678706 |
0.651 |
|
| 2016 |
Sinha RK, Flynn RP, Fernandez JA, Xu X, Martin G, Kupriyanov S, Griffin JH, Blazar BR. Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells Blood. 128: 808-808. DOI: 10.1182/Blood.V128.22.808.808 |
0.629 |
|
| 2016 |
Radojcic V, Flynn RP, Chung J, Du J, Perkey E, Paz K, Zaiken M, Friedman A, Yan M, Siebel CW, Blazar BR, Maillard I. Notch Signaling Mediated By Dll1/4 Notch Ligands Controls the Pathogenesis of Both Multi-Organ System Non-Sclerodermatous and Sclerodermatous Chronic Graft-Versus-Host Disease Blood. 128: 805-805. DOI: 10.1182/Blood.V128.22.805.805 |
0.731 |
|
| 2016 |
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Salem A, Fontbrune FSd, Na I, Livius P, ... ... Flynn RP, et al. Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib Blood. 128: 4561-4561. DOI: 10.1182/Blood.V128.22.4561.4561 |
0.459 |
|
| 2016 |
Wu Y, Schutt SD, Flynn RP, Zhang M, Nguyen HD, Blazar BR, Yu X. MiR-17-92 Is Required for the Pathogenicity of T and B Cells in Chronic Gvhd Blood. 128: 4535-4535. DOI: 10.1182/Blood.V128.22.4535.4535 |
0.613 |
|
| 2016 |
Du J, Flynn RP, Paz K, Vulic A, Robinson TM, Lineburg KE, Macdonald KPA, Hill GR, Serody JS, Maillard I, Panoskaltsis-Mortari A, Schacker T, Luznik L, Blazar BR. Pirfenidone Reverses Murine Chronic Graft Versus Host Disease Blood. 128: 1158-1158. DOI: 10.1182/Blood.V128.22.1158.1158 |
0.63 |
|
| 2015 |
Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S, Singh K, Giver C, Hamby K, Stempora L, Garrett A, Chen J, Betz KM, Ziegler CG, Tharp GK, et al. Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. Science Translational Medicine. 7: 315ra191. PMID 26606970 DOI: 10.1126/Scitranslmed.Aad3231 |
0.713 |
|
| 2015 |
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, ... ... Flynn R, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 29: 2062-8. PMID 26228813 DOI: 10.1038/Leu.2015.212 |
0.562 |
|
| 2015 |
Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 125: 4085-94. PMID 25852057 DOI: 10.1182/Blood-2014-08-595470 |
0.68 |
|
| 2015 |
Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknect E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 125: 3335-46. PMID 25814530 DOI: 10.1182/Blood-2014-09-603357 |
0.764 |
|
| 2015 |
Blazar BR, Flynn R, Lee R, Marcucci G, Caliguiri MA, Heeger PS. Strategies to inhibit alloantibody production in alloprimed murine recipients of hematopoietic stem cell grafts. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 15: 931-41. PMID 25762193 DOI: 10.1111/Ajt.13125 |
0.698 |
|
| 2015 |
Hechinger AK, Smith BA, Flynn R, Hanke K, McDonald-Hyman C, Taylor PA, Pfeifer D, Hackanson B, Leonhardt F, Prinz G, Dierbach H, Schmitt-Graeff A, Kovarik J, Blazar BR, Zeiser R. Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD. Blood. 125: 570-80. PMID 25352130 DOI: 10.1182/Blood-2014-06-581793 |
0.584 |
|
| 2015 |
Blazar BR, O'Connor RS, Milone MC, Dustin ML, Riley JL, Vincent BG, Serody JS, Flynn RP, Paz K, Du J, Panoskaltsis-Mortari A, Jeffrey M, Ahmed R, Turka LAA, Freeman GJ, et al. Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease Blood. 126: SCI-8-SCI-8. DOI: 10.1182/Blood.V126.23.Sci-8.Sci-8 |
0.51 |
|
| 2015 |
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, Sicre de Fontbrune F, Na I, Penter L, ... ... Flynn RP, et al. Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients Blood. 126: 858-858. DOI: 10.1182/Blood.V126.23.858.858 |
0.548 |
|
| 2015 |
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, ... ... Flynn R, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey Leukemia. DOI: 10.1038/leu.2015.212 |
0.516 |
|
| 2014 |
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. The Journal of Clinical Investigation. 124: 4867-76. PMID 25271622 DOI: 10.1172/Jci75328 |
0.746 |
|
| 2014 |
Alexander KA, Flynn R, Lineburg KE, Kuns RD, Teal BE, Olver SD, Lor M, Raffelt NC, Koyama M, Leveque L, Le Texier L, Melino M, Markey KA, Varelias A, Engwerda C, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. The Journal of Clinical Investigation. 124: 4266-80. PMID 25157821 DOI: 10.1172/Jci75935 |
0.557 |
|
| 2014 |
Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 123: 3988-98. PMID 24820310 DOI: 10.1182/Blood-2014-03-562231 |
0.808 |
|
| 2014 |
Zanin-Zhorov A, Flynn R, Luznik L, Panoskaltsis-Mortari A, Jing D, Goodman K, Weiss J, Nyuydzefe M, Chen W, Serody JS, MacDonald KP, Hill GR, O'Shea J, Roche M, Weiss S, et al. A Selective and Potent Rock 2 Inhibitor (KD025) Decreases Human STAT3-Dependent IL-21 and IL-17 Production and Experimental Chronic Graft-Versus-Host Disease (cGVHD) Blood. 124: 540-540. DOI: 10.1182/Blood.V124.21.540.540 |
0.637 |
|
| 2014 |
Flynn RP, Goodman K, Qi J, Jing D, Panoskaltsis-Mortari A, Yi Z, Dong C, Liu X, MacDonald KPA, Hill GR, Serody JS, Murphy WJ, Luznik L, Maillard I, Koreth J, et al. Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies Blood. 124: 535-535. DOI: 10.1182/Blood.V124.21.535.535 |
0.691 |
|
| 2014 |
Furlan SN, Watkins B, Flynn RP, Ramakrishnan S, Singh K, Giver CR, Hanby K, Stempora L, Garrett AP, Ziegler CG, Tharp G, Bosinger S, Blazar BR, Waller EK, Kean LS. Defining the Primate T Cell Transcriptome during Graft Versus Host Disease: New Data Implicating the Hedgehog and Aurora Kinase Pathways in Pathogenesis and Prevention Blood. 124: 2432-2432. DOI: 10.1182/Blood.V124.21.2432.2432 |
0.679 |
|
| 2014 |
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Yang C, Towns W, Lehman A, Johnson A, Devine S, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, et al. Abstract 2591: Ibrutinib can reverse established chronic graft-versus-host disease, which is dependent upon IL-2 inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK)-driven lymphocyte activation Cancer Research. 74: 2591-2591. DOI: 10.1158/1538-7445.Am2014-2591 |
0.696 |
|
| 2014 |
Alexander K, Flynn R, Lineburg K, Kuns R, Janela B, Teal B, Olver S, Lor M, Raffelt N, Koyama M, Leveque L, Texier LL, Melino M, Markey K, Varelias A, et al. CSF-1-Dependant M2 Macrophages Mediate Chronic Graft-Versus-Host Disease Transplantation. 98: 390-391. DOI: 10.1097/01.Tp.0000452130.27963.71 |
0.364 |
|
| 2014 |
Alexander K, Flynn R, Lineburg K, Kuns R, Janela B, Teal B, Olver S, Lor M, Raffelt N, Koyama M, Leveque L, Texier LL, Melino M, Markey K, Varelias A, et al. CSF-1-Dependant M2 Macrophages Mediate Chronic Graft-Versus-Host Disease.: Abstract# D2343 Transplantation. 98: 390-391. DOI: 10.1097/00007890-201407151-01280 |
0.354 |
|
| 2013 |
Flynn R, Du J, Veenstra R, Panoskaltsis-Mortari A, Price A, Taylor PA, Freeman GJ, Browning JL, Serody J, Murphy WJ, Munn D, Sarantopoulos S, Luznik L, Maillard I, Koreth J, et al. Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model Blood. 122: 292-292. DOI: 10.1182/Blood.V122.21.292.292 |
0.819 |
|
| 2012 |
Veenstra RG, Taylor PA, Zhou Q, Panoskaltsis-Mortari A, Hirashima M, Flynn R, Liu D, Anderson AC, Strom TB, Kuchroo VK, Blazar BR. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood. 120: 682-90. PMID 22677125 DOI: 10.1182/Blood-2011-10-387977 |
0.803 |
|
| 2012 |
Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A, Blazar BR. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 119: 1570-80. PMID 22072556 DOI: 10.1182/Blood-2011-07-364414 |
0.632 |
|
| 2011 |
Flynn RP, Zacharias J, Zhou X, Cannon ML, Philpott NJ. Non-integrating lentiviral vectors for specific killing of Epstein-Barr virus nuclear antigen 1-positive B cell lymphoma cells. The Journal of Gene Medicine. 13: 487-96. PMID 21850667 DOI: 10.1002/Jgm.1601 |
0.476 |
|
| Show low-probability matches. |